Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWeill Medical College of Cornell University

About this trial

During breast surgery, sensory nerves are cut which may lead to reduced sensation and pain. Surgical reinnervation techniques have been developed with the aim of improving postoperative sensation by preserving the nerves and connecting them to the nipple and areola. The investigators aim to compare postoperative sensation and patient reported outcomes in patients undergoing reinnervation versus those not undergoing reinnervation to determine if there is a difference. The investigators will investigate this in patients undergoing gender-affirming mastectomy, implant-based breast reconstruction and autologous breast reconstruction. The investigators will use various tools that measure sensation quantitatively.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age over 18

Patient is scheduled for gender mastectomy surgery (including nipple sparing mastectomy and mastectomy with free nipple graft) or NSM with breast implant or autologous reconstruction

Patient is capable and willing to provide informed consent

Disqualifiers

Patient has a nerve condition that does not allow for assessment of sensation

Any subject who at the discretion of the Investigator is not suitable for inclusion in the study or is unlikely to comply with follow-up schedule

Currently prescribed medication known to impact nerve regeneration or to cause peripheral neuropathy

Bilateral reconstruction with non-uniform treatment (i.e. 1 reconstructed breast is non-neurotized, 1 reconstructed breast is neurotized)

Trial population

Massachusetts General Hospital (MGH) and Weill Cornell Medicine (WCM) are ideally suited for enrollment of patients in this study. Both institutions are high-volume center of expertise for gender affirming mastectomy and breast reconstructions as well as peripheral nerve surgery. Patients will be matched by BMI, age and mastectomy weight. Patients scheduled to undergo gender affirming mastectomy or breast reduction surgery at MGH and WCM will be evaluated for the study and will be presented with the option to hear about the study by our research assistant. Those interested in the study will be presented with all the necessary details required by the IRB including a study fact sheet. Verbal consent will be obtained and documented.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Sensory testing

    Diagnostic test

    Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)

Treatment groups

400 Participants
are divided into 4 treatment groups
Group A: Nipple sparing mastectomy (NSM) and implant reconstruction1 intervention
Group B: Nipple sparing mastectomy (NSM) and autologous reconstruction1 intervention
Group C: Gender mastectomy with free nipple grafting1 intervention
Group D: Control patients matched by surgical procedure, age, BMI and mastectomy weight.1 intervention

Trial outcomes

Primary outcomes

1

Change in Breast Q scores

All BREAST-Q scores range from 0-100. The scores are computed from the responses to the separate questions by adding them together and converting the score to a scale from 0 to 100 (similar to conversion into a percentage). A higher score means high satisfaction or better health-related quality of life.

Time frame
preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year
2

Change in Gender-Q scores

All Gender-Q scores range from 0-100. The scores are computed from the responses to the separate questions by adding them together and converting the score to a scale from 0 to 100 (similar to conversion into a percentage). A higher score means high satisfaction or better health-related quality of life.

Time frame
preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year
3

Change in cold detection threshold

Thermal detection measured by Medoc TSA system

Time frame
preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year
4

Change in warm detection threshold

Thermal detection measured by Medoc TSA system

Time frame
preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year

Secondary outcomes

1

Change in Breast Q scores long term

All BREAST-Q scores range from 0-100. The scores are computed from the responses to the separate questions by adding them together and converting the score to a scale from 0 to 100 (similar to conversion into a percentage). A higher score means high satisfaction or better health-related quality of life.

Time frame
Annually at 2-10 years post-operation
2

Change in Gender Q scores long term

All Gender-Q scores range from 0-100. The scores are computed from the responses to the separate questions by adding them together and converting the score to a scale from 0 to 100 (similar to conversion into a percentage). A higher score means high satisfaction or better health-related quality of life.

Time frame
Annually at 2-10 years post-operation
3

Change in vibration sensation

Measured by tuning fork

Time frame
Annually at 2-10 years post-operation
4

Change in Tinel sensation

Measure on physical exam

Time frame
Annually at 2-10 years post-operation

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Medical College of Cornell University

Lead sponsor

Massachusetts General Hospital

Collaborator